Success Metrics

Clinical Success Rate

83.3%

Based on 5 completed trials

Completion Rate

83%(5/6)

Active Trials

0(0%)

Results Posted

100%(5 trials)

Terminated

1(14%)

Phase Distribution

Ph phase_1

29%

Ph early_phase_1

14%

Ph not_applicable

29%

Ph phase_2

14%

Ph phase_3

14%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Early Phase 1First-in-human

1(14.3%)

Phase 1Safety & dosage

2(28.6%)

Phase 2Efficacy & side effects

1(14.3%)

Phase 3Large-scale testing

1(14.3%)

N/ANon-phased studies

2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(1)

Other(1)

Detailed Status

Completed5

Terminated1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Phase 3

Trials by Phase

Early Phase 11 (14.3%)

Phase 12 (28.6%)

Phase 21 (14.3%)

Phase 31 (14.3%)

N/A2 (28.6%)

Trials by Status

terminated114%

unknown114%

completed571%

Recent Activity

0 active trials

Showing 5 of 7

completedearly_phase_1

Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation

NCT03083353

completedphase_3

Efficacy of Isradipine in Early Parkinson Disease

NCT02168842

completednot_applicable

Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder

NCT01658150

completedphase_1

Improving Buprenorphine Detoxification Outcomes With Isradipine

NCT01895270

terminatedphase_2

Adjunctive Isradipine for the Treatment of Bipolar Depression

NCT01784666

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT03083353Early Phase 1

Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation

Completed

NCT02168842Phase 3

Efficacy of Isradipine in Early Parkinson Disease

Completed

NCT01658150Not Applicable

Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder

Completed

NCT01895270Phase 1

Improving Buprenorphine Detoxification Outcomes With Isradipine

Completed

NCT01784666Phase 2

Adjunctive Isradipine for the Treatment of Bipolar Depression

Terminated

NCT02136823Not Applicable

Impact of Persistent Conductances on Motor Unit Firing in SCI

Unknown

NCT00593463Phase 1

Drug Discrimination in Methadone-Maintained Humans Study 1

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7